Champème M H, Bièche I, Hacène K, Lidereau R
Laboratoire d'Oncogénétique, Centre René Huguenin, Saint-Cloud, France.
Mol Carcinog. 1994 Dec;11(4):189-91. doi: 10.1002/mc.2940110403.
As the prognostic significance of the three most frequently amplified oncogenes in breast cancer (c-myc, int-2/FGF3, and c-erbB-2/neu) is still unclear, and as the amplification of these genes appears to be mutually exclusive, we investigated the prognostic significance of oncogene amplification per se by multivariate analysis in a group of 112 primary human breast cancer cases. Amplification of at least one gene (c-myc, int-2/FGF3, or c-erbB-2/neu), progesterone receptor status, and pathological tumor size were the only independent variables predictive of metastasis-free survival. Moreover, we constructed prognostic profiles by computing risks associated with the three parameters predictive of poor survival and discriminated high-, moderate-, and low-risk categories.
由于乳腺癌中三种最常扩增的致癌基因(c-myc、int-2/FGF3和c-erbB-2/neu)的预后意义仍不明确,且这些基因的扩增似乎相互排斥,我们通过多变量分析在一组112例原发性人类乳腺癌病例中研究了致癌基因扩增本身的预后意义。至少一种基因(c-myc、int-2/FGF3或c-erbB-2/neu)的扩增、孕激素受体状态和病理肿瘤大小是预测无转移生存期的唯一独立变量。此外,我们通过计算与预测不良生存的三个参数相关的风险构建了预后概况,并区分了高、中、低风险类别。